Comparative Pharmacology
Head-to-head clinical analysis: AMICAR versus CYKLOKAPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMICAR versus CYKLOKAPRON.
AMICAR vs CYKLOKAPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
4-5 g IV loading dose over 1 hour, followed by 1 g/hour IV continuous infusion for 8 hours or until bleeding controlled; oral: 5 g PO initially, then 1-1.25 g PO every hour as needed.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 2 hours (range 1-3.5 hours). After high doses or renal impairment, half-life may prolong (up to 5-10 hours).
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Renal: >99% of absorbed dose excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic